Solriamfetol 150 mg
SOL-BED-301
Phase 3 small_molecule active
Quick answer
Solriamfetol 150 mg for Binge-Eating Disorder is a Phase 3 program (small_molecule) at Axsome Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Axsome Therapeutics
- Indication
- Binge-Eating Disorder
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active